REVELATION BIOSCIENCES, INC. (REVB) Form 8-K — Nov 5, 2026
Revelation Biosciences reported a Q3 2026 net loss of $3.3 million ($5.92 per share), widening from $1.9 million a year earlier, as operating expenses more than doubled to $3.4 million. The company held $9.1 million in cash at September 30, 2026, down from $10.7 million at year-end 2025, and says that is enough to fund operations only into the second quarter of 2027 — pointing to a likely near-term financing and dilution event.
Key figures
- Revenue
- 0
- Guidance
- Cash sufficient to fund operations into the second quarter of 2027
- Cash Position
- 9121630
- Cash dec 31 2025
- 10700331
- Tam estimate usd
- $94 billion for Gemini (independent market assessment)
- Ga expense q3 2026
- 1870678
- Shares outstanding
- 683442
- Rnd expense q3 2026
- 1512898
- Weighted avg shares q3 2026
- 559596
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.